OnconetixONCO
ONCO
About: Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Employees: 5
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
18% more funds holding
Funds holding: 11 [Q4 2024] → 13 (+2) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
2.29% less ownership
Funds ownership: 4.62% [Q4 2024] → 2.34% (-2.29%) [Q1 2025]
89% less capital invested
Capital invested by funds: $242K [Q4 2024] → $26.7K (-$215K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for ONCO.
Financial journalist opinion
Based on 3 articles about ONCO published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Onconetix, Inc. (NASDAQ: ONCO ) related to its merger with Ocuvex Therapeutics, Inc. Upon completion of the proposed transaction, each share of Ocuvex will be exchanged for a number of Onconetix shares based on a defined exchange ratio, resulting in Ocuvex shareholders owning approximately 90% of the combined company and Onconetix shareholders owning approximately 10%. Is it a fair deal?
Neutral
Business Wire
2 weeks ago
ONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Onconetix, Inc. (NASDAQ: ONCO) and Ocuvex Therapeutics, Inc. is fair to Onconetix shareholders. Upon completion of the proposed transaction, Onconetix shareholders will own 10% of the combined company. Halper Sadeh encourages Onconetix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@hal.
Neutral
GlobeNewsWire
2 weeks ago
Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement
CINCINNATI, July 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates, today announced that they have entered into a definitive merger agreement (the “Merger Agreement”).
Neutral
GlobeNewsWire
1 month ago
Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel
CINCINNATI, Ohio, June 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today reported that on June 11, 2025, the Company received a decision from the Nasdaq Hearings Panel granting the Company's request for continued listing on The Nasdaq Stock Market, subject to the Company demonstrating compliance with the Nasdaq Listing Rule 5550(a)(2) (the “Periodic Filing Listing Rule”) by June 13, 2025 and the Nasdaq Listing Rule 5250(c)(1) (the “Bid Price Listing Rule”) on or before June 30, 2025.
Neutral
GlobeNewsWire
1 month ago
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders
CINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that the Company's stockholders have approved a proposal to effect a reverse split, which was voted on at the Company's 2025 special meeting of stockholders (the “Special Meeting”) held on May 30, 2025, and that its Board of Directors (the “Board of Directors” or “Board”) approved a 1-for-85 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on June 13, 2025.
Neutral
GlobeNewsWire
2 months ago
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on May 20, 2025 indicating that the Company's failure to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the “10-Q”) is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”).
Neutral
Business Wire
2 months ago
Onco-Innovations Uplists to Cboe Canada
TORONTO--(BUSINESS WIRE)---- $ONCO #Cboe--Cboe Canada is pleased to announce that Onco-Innovations Limited is available for trading under the ticker symbol ONCO.
Neutral
GlobeNewsWire
3 months ago
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Cincinnati, OH, April 30, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on April 24, 2025 indicating that the Company's failure to file its Annual Report on Form 10-K for the fiscal year ended December 30, 2024 is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”). This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.
Neutral
GlobeNewsWire
4 months ago
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced that new clinical data of Proclarix® was presented on March 23, 2025 during the 2025 European Association of Urology (EAU) congress, which data further demonstrates the strong clinical performance of Proclarix® in a Danish cohort.
Neutral
GlobeNewsWire
4 months ago
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress
CINCINNATI, March 19, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced that an abstract has been accepted for presentation at the 2025 European Association of Urology (EAU) congress taking place March 21-24, 2025, in Madrid, Spain.
Charts implemented using Lightweight Charts™